Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2005 Oct 19;2005(4):CD003345.
doi: 10.1002/14651858.CD003345.pub2.

Systemic administration of local anesthetic agents to relieve neuropathic pain

V Challapalli, I W Tremont-Lukats, E D McNicol, J Lau, D B Carr
Meta-Analysis

Systemic administration of local anesthetic agents to relieve neuropathic pain

V Challapalli et al. Cochrane Database Syst Rev. .

Abstract

Background: Lidocaine, mexiletine, tocainide, and flecainide are local anesthetics which give an analgesic effect when administered orally or parenterally. Early reports described the use of intravenous lidocaine or procaine to relieve cancer and postoperative pain (Keats 1951; Gilbert 1951; De Clive-Lowe 1958; Bartlett 1961). Interest reappeared decades later when patient series and clinical trials reported that parenteral lidocaine and its oral analogs tocainide, mexiletine, and flecainide relieved neuropathic pain in some patients (Boas 1982; Lindblom 1984; Petersen 1986; Dunlop 1988; Bach 1990; Awerbuch 1990). With the recent publication of clinical trials with high quality standards, we have reviewed the use of systemic lidocaine and its oral analogs in neuropathic pain to update our knowledge, to measure their benefit and harm, and to better define their role in therapy.

Objectives: To evaluate pain relief and adverse effect rates between systemic local anesthetic-type drugs and other control interventions.

Search strategy: We searched MEDLINE (1966 through 15 May 2004), EMBASE (January 1980 to December 2002), Cancer Lit (through 15 December 2002), Cochrane Central Register of Controlled Trials (2nd Quarter, 2004), System for Information on Grey Literature in Europe (SIGLE), and LILACS, from January 1966 through March 2001. We also hand searched conference proceedings, textbooks, original articles and reviews.

Selection criteria: We included trials with random allocation, that were double blinded, with a parallel or crossover design. The control intervention was a placebo or an analgesic drug for neuropathic pain from any cause.

Data collection and analysis: We collected efficacy and safety data from all published and unpublished trials. We calculated combined effect sizes using continuous and binary data for pain relief and adverse effects as primary and secondary outcome measurements, respectively.

Main results: Thirty-two controlled clinical trials met the selection criteria; two were duplicate articles. The treatment drugs were intravenous lidocaine (16 trials), mexiletine (12 trials), lidocaine plus mexiletine sequentially (one trial), and tocainide (one trial). Twenty-one trials were crossover studies, and nine were parallel. Lidocaine and mexiletine were superior to placebo [weighted mean difference (WMD) = -11; 95% CI: -15 to -7; P <0.00001], and limited data showed no difference in efficacy (WMD = -0.6; 95% CI: -7 to 6), or adverse effects versus carbamazepine, amantadine, gabapentin or morphine. In these trials, systemic local anesthetics were safe, with no deaths or life-threatening toxicities. Sensitivity analysis identified data distribution in three trials as a probable source of heterogeneity. There was no publication bias.

Authors' conclusions: Lidocaine and oral analogs were safe drugs in controlled clinical trials for neuropathic pain, were better than placebo, and were as effective as other analgesics. Future trials should enroll specific diseases and test novel lidocaine analogs with better toxicity profiles. More emphasis is necessary on outcomes measuring patient satisfaction to assess if statistically significant pain relief is clinically meaningful.

Notes: Notes 2017 A restricted search in June 2017 did not identify any potentially relevant studies likely to change the conclusions. Therefore, this review has now been stabilised following discussion with the authors and editors. If appropriate, we will update the review if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions. 2019 We performed another restricted search in September 2019 but did not identify any potentially relevant studies likely to change the conclusions. Therefore, this review has now been stabilised following discussion with the authors and editors, and we will reassess the review for updating in 2020. If appropriate, we will update the review sooner if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions. 2020 We performed another restricted search in September 2020 but again did not identify any potentially relevant studies likely to change the conclusions. This area of research is not active and therefore this review has now been stabilised following discussion with the authors and editors; we will reassess the review for updating in 2025. If appropriate, we will update the review sooner if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1
1
Funnel plot of comparison 01, outcome 01. The trials by Baranowski, Fassoulaki and Stracke are on or outside the 95% confidence intervals.
1.1
1.1. Analysis
Comparison 1: Efficacy of lidocaine or mexiletine vs. placebo control, Outcome 1: Post intervention/placebo mean VAS (0‐100) pain scores (Random effects model)
1.2
1.2. Analysis
Comparison 1: Efficacy of lidocaine or mexiletine vs. placebo control, Outcome 2: Significant pain relief by response rates
2.1
2.1. Analysis
Comparison 2: Subgroup analyses for comparison 01, Outcome 1: By sample size
2.2
2.2. Analysis
Comparison 2: Subgroup analyses for comparison 01, Outcome 2: By time of outcome measurement
2.3
2.3. Analysis
Comparison 2: Subgroup analyses for comparison 01, Outcome 3: By time of outcome measurement (minus Stracke trial)
2.4
2.4. Analysis
Comparison 2: Subgroup analyses for comparison 01, Outcome 4: By time of outcome measurement (minus 3 trials with wide data spread)
2.5
2.5. Analysis
Comparison 2: Subgroup analyses for comparison 01, Outcome 5: By trial design
2.6
2.6. Analysis
Comparison 2: Subgroup analyses for comparison 01, Outcome 6: By methodological quality
2.7
2.7. Analysis
Comparison 2: Subgroup analyses for comparison 01, Outcome 7: By etiologic category
3.1
3.1. Analysis
Comparison 3: Efficacy of intravenous lidocaine or its oral analogs vs. other analgesics, Outcome 1: Mean pain scores post intervention/control
4.1
4.1. Analysis
Comparison 4: Adverse effects: Lidocaine or oral analogs vs. placebo, Outcome 1: Patients with adverse effects
5.1
5.1. Analysis
Comparison 5: Adverse effects: Lidocaine or oral analogs vs. other analgesics, Outcome 1: Patients with adverse effects
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD003345

Similar articles

  • Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults.
    Weibel S, Jelting Y, Pace NL, Helf A, Eberhart LH, Hahnenkamp K, Hollmann MW, Poepping DM, Schnabel A, Kranke P. Weibel S, et al. Cochrane Database Syst Rev. 2018 Jun 4;6(6):CD009642. doi: 10.1002/14651858.CD009642.pub3. Cochrane Database Syst Rev. 2018. PMID: 29864216 Free PMC article.
  • Topical clonidine for neuropathic pain in adults.
    Serednicki WT, Wrzosek A, Woron J, Garlicki J, Dobrogowski J, Jakowicka-Wordliczek J, Wordliczek J, Zajaczkowska R. Serednicki WT, et al. Cochrane Database Syst Rev. 2022 May 19;5(5):CD010967. doi: 10.1002/14651858.CD010967.pub3. Cochrane Database Syst Rev. 2022. PMID: 35587172 Free PMC article.
  • Sertindole for schizophrenia.
    Lewis R, Bagnall AM, Leitner M. Lewis R, et al. Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
  • Oxycodone for cancer-related pain.
    Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS, Page AJ, Chi Y. Schmidt-Hansen M, et al. Cochrane Database Syst Rev. 2022 Jun 9;6(6):CD003870. doi: 10.1002/14651858.CD003870.pub7. Cochrane Database Syst Rev. 2022. PMID: 35679121 Free PMC article.
  • Interventions for infantile haemangiomas of the skin.
    Novoa M, Baselga E, Beltran S, Giraldo L, Shahbaz A, Pardo-Hernandez H, Arevalo-Rodriguez I. Novoa M, et al. Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD006545. doi: 10.1002/14651858.CD006545.pub3. Cochrane Database Syst Rev. 2018. PMID: 29667726 Free PMC article.
See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Attal 2000 {published data only}
    1. Attal N, Gaude V, Brasseur L, Dupuy M, Guirimand F, Parker F, et al. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology 2000;54(3):564-74. - PubMed
Attal 2004 {published data only}
    1. Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 2004;62(2):218-25. - PubMed
Backonja 2000 {unpublished data only}
    1. Backonja MM, Tremont-Lukats IW. Pain relief from lidocaine at three different doses: A randomized controlled trial. Neurology 2000;54(S3):A81.
Baranowski 1999 {published data only}
    1. Baranowski AP, De Courcey J, Bonello E. A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. Journal of Pain and Symptom Management 1999;17(6):429-33. - PubMed
Bruera 1992 {published data only}
    1. Bruera E, Ripamonti C, Brennis C, et al. A randomized double-blind controlled trial of intravenous lidocaine in the treatment of neuropathic cancer patients. Journal of Pain Symptom Management 1992;7:138-141. - PubMed
Chabal 1992 {published data only}
    1. Chabal C, Jacobson L, Mariano A, Chaney E, Britell CW. The use of oral mexilitine for the treatment of pain after peripheral nerve injury. Anesthesiology 1992;76(4):513-7. - PubMed
Chiou‐Tan 1996 {published data only}
    1. Chiou-Tan FY, Tuel SM, Johnson JC, Priebe MM, Hirsh DD, Strayer JR. Effect of mexilitine on spinal cord injury dysesthetic pain. American Journal of Physical Medicine and Rehabilitation 1996;75(2):84-7. - PubMed
Dejgard 1988 {published data only}
    1. Dejgard A, Petersen P, Kastrup J. Mexilitine for treatment of chronic painful diabetic neuropathy. Lancet 1988;1(8575-6):9-11. - PubMed
Ellemann 1989 {published data only}
    1. Elleman K, Sjogren P, Banning AM, et al. Trial of intravenous lidocaine on painful neuropathy in cancer patients. Clinical Journal Pain 1989;5(4):291-4. - PubMed
Fassoulaki 2002 {published data only}
    1. Fassoulaki A, Patris K, Sarantopoulos C, Hogan Q. The analgesic effect of gabapentin and mexilitine after breast surgery for cancer. Anesthesia and Analgesia 2002;95(4):985-91. - PubMed
Galer 1996 {published data only}
    1. Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexilitine: a prospective study. Journal of Pain Symptom Management 1996;12(3):161-7. - PubMed
Kastrup 1987 {published data only}
    1. Kastrup J, Petersen P, Dejgard A, Angelo HR, Hilsted J. Intravenous lidocaine infusion - a new treatment of chronic painful diabetic neuropathy? Pain 1987;28(1):69-75. - PubMed
Kemper 1998 {published data only}
    1. Kemper CA, Kent G, Burton S, Deresinski SC. Mexiletine for HIV-infected patients with painful peripheral neuropathy: a double-blind, placebo-controlled, crossover treatment trial. Journal of Acquired Immune Deficiency Syndrome Human Retrovirology 1998;19(4):367-72. - PubMed
Kieburtz 1998 {published data only}
    1. Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Hall CD, Ellis RJ, et al. A randomized trial of amitriptyline and mexilitine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998;51(6):1682-8. - PubMed
Kvarnstrom 2003 {published data only}
    1. Kvarnstrom A, Karlsten R, Quiding H, Emanuelsson BM, Gordh, T. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol Scand 2003;47:868-77. - PubMed
Kvarnstrom 2004 {published data only}
    1. Kvarnstrom A, Karlsten R, Quiding H, Gordh T. The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury. Acta Anaesthesiol Scand 2004;48:498-506. - PubMed
Lindstrom 1987 {published data only}
    1. Lindstrom P, Lindblom U. The analgesic effect of tocainide in trigeminal neuralgia. Pain 1987;28(1):45-50. - PubMed
Marchettini 1992 {published data only}
    1. Marchettini P, Lacerenza M, Marangoni C, et al. Lidocaine test in neuralgia. Pain 1992;48(3):377-82. - PubMed
Matsuoka 1996 {unpublished data only}
    1. Matsuoka K, Hirata Y, Kanazawa Y. Optimal dose evaluation of mexilitine hydrochloride (MX-PDN) in patients with diabetic polyneuropathy. Igaku Yakugaku 1996;36(4):665-693.
Matsuoka 1997 {published data only}
    1. Matsuoka K, Kanazawa Y, Ohtake M, Kaihara S. Double-blind trial of mexilitine on painful diabetic neuropathy. Diabetologia 1997;40(S1):A559.
Medrik 1999 {published data only}
    1. Medrik-Goldberg T, Lifschitz D, Pud D, Adler R, Eisenberg E. Intravenous lidocaine, amantadine, and placebo in the treatment of sciatica: a double-blind, randomized, controlled study. Regional Anesthesia and Pain Medicine 1999;24(6):534-40. - PubMed
Oskarsson 1997 {published and unpublished data}
    1. Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexilitine Study Group. Diabetes Care 1997;20(10):1594-7. - PubMed
Rowbotham 1991 {published data only}
    1. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991;41(7):1024-8. - PubMed
Sörensen 1995 {published data only}
    1. Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M. Pain Analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine.. Scandinavian Journal of Rheumatology 1995;24(6):360-5. - PubMed
Stracke 1994 {published data only}
    1. Stracke H, Meyer U, Schumacher H, Armbrecht U, Beroniade S, Buch K-D, et al. Mexiletine in the treatment of painful diabetic neuropathy [Mexiletin in der Behandlung der schmertzhaften diabetischen Neuropathie]. Med Klin 1994;89(3):124-131. - PubMed
Wallace 1996 {published data only}
    1. Wallace MS, Dyck JB, Rossi SS, Yaksh TL. Computer-controlled lidocaine infusion for the evaluation of neuropathic pain after peripheral nerve injury. Pain 1996;66(1):69-77. - PubMed
Wallace 2000a {published data only}
    1. Wallace MS, Ridgeway BM, Leung AY, Gerayli A, Yaksh TL. Concentration-effect relationship of intravenous lidocaine on the allodynia of complex regional pain syndrome types I and II. Anesthesiology 2000;92(1):75-83. - PubMed
Wallace 2000b {published data only}
    1. Wallace MS, Magnuson S, Ridgeway B. Efficacy of oral mexiletine for neuropathic pain with allodynia: a double-blind, placebo-controlled, crossover study. Regional Anesthesia and Pain Medicine 2000;25(5):459-67. - PubMed
Wright 1997 {published data only}
    1. Wright JM, Oki JC, Graves L 3rd. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Annals of Pharmacotherapy 1997;31(1):29-34. - PubMed
Wu 2002 {published data only}
    1. Wu CL, Tella P, Staats PS, Vaslav R, Kazim DA, Wesselmann U, et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double-blind, active placebo-controlled, crossover trial. Anesthesiology 2002;96(4):841-8. - PubMed

References to studies excluded from this review

Ando 2000 {published data only}
    1. Ando K, Wallace MS, Braun J, Schulteis G. Effect of oral mexiletine on capsaicin-induced allodynia and hyperalgesia: a double-blind, placebo-controlled, crossover study. Reg Anesth Pain Med 2000;25(5):468-74. - PubMed
Bach 1990 {published data only}
    1. Bach FW, Jensen TS, Kastrup J, Stigsby B, Dejgard A. The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy [see comments]. Pain 1990;40(1):29-34. - PubMed
Català 1994 {published data only}
    1. Català E, Ferrándiz M, Aliaga L, Serra R, Castro MA, Villar-Landeira JM. Intravenous lidocaine compared with sympathetic blocks as treatment for post-herpetic neuralgia. A 1-year survey. The Pain Clinic 1994;7(3):205-210.
Dirks 2000 {published data only}
    1. Dirks J, Fabricius P, Petersen KL, Rowbotham MC, Dahl JB. The effect of systemic lidocaine on pain and secondary hyperalgesia associated with the heat/capsaicin sensitization model in healthy volunteers. Anesthesia & Analgesia 2000;91(4):967-72. - PubMed
Dunlop {published data only}
    1. Dunlop RJ, Hockley JM, Tate T, Turner P. Flecainide in cancer nerve pain. Lancet 1991;337:1347. - PubMed
Gottrup 2000 {published data only}
    1. Gottrup H, Hansen PO, Arendt-Nielsen L, Jensen TS. Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans. British Journal of Anaesthesia 2000;84(2):155-162. - PubMed
Kastrup 1986 {published data only}
    1. Kastrup J, Petersen P, Dejgard A, Hilsted J. Treatment of chronic painful diabetic neuropathy with intravenous lidocaine infusion. Br Med J (Clin Res Ed) 1986;292:173. - PMC - PubMed
Keats 1951 {published data only}
    1. Keats AS, D'Alessandro GL, Beecher HK. A controlled study of pain relief by intravenous procaine. Journal of the American Medical Association 1951;147:1761-3. - PubMed
Posner 1994 {published data only}
    1. Posner IA. Treatment of fibromyalgia syndrome with intravenous lidocaine: A prospective, randomized pilot study. Journal of Musculoskeletal Pain 1994;2/4:55-65.
Reljanovic 1996 {unpublished data only}
    1. Reljanovic M, Pibernik M, Beer Z, et al. Mexilitine treatment in painful diabetic polyneuropathy. Diabetologia 1996;39(S1):A260.
Rowlingson 1980 {published data only}
    1. Rowlingson JC, DiFazio CA, Foster J, Carron H. Lidocaine as an analgesic for experimental pain. Anesthesiology 1980;52(1):20-2. [MEDLINE: ] - PubMed
Sakurai 1999 {published data only}
    1. Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 1999;162:162-168. - PubMed
Stracke 1992 {published data only}
    1. Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992;15(11):1550-5. - PubMed
Wallace 1997 {published data only}
    1. Wallace MS, Laitin S, Licht D, Yaksh TL. Concentration-effect relations for intravenous lidocaine infusions in human volunteers: effects on acute sensory thresholds and capsaicin- evoked hyperpathia. Anesthesiology 1997;86(6):1262-72. - PubMed

Additional references

Abdi 1998
    1. Abdi S, Lee DH, Chung JM. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesthesia and Analgesia 1998;87(6):1360-6. - PubMed
Awerbuch 1990
    1. Awerbuch GI, Sandyk R. Mexiletine for thalamic pain syndrome. International Journal of Neuroscience 1990;55:129-133. - PubMed
Bartlett 1961
    1. Bartlett EE, Hutaserani O. Xylocaine for the relief of postoperative pain. Anesthesia and Analgesia 1961;40:296-304. - PubMed
Boas 1982
    1. Boas RA, Covino BG, Shahnarian A. Analgesic response to i.v. lignocaine. British Journal of Anesthesia 1982;54:501-505. - PubMed
Bowsher 1991
    1. Bowsher D. Neurogenic pain syndromes and their management. In: Wells JCD, Woolf CJ, editors(s). Brit Med Bull. Vol. 47. Edinburgh: Churchill Livingstone, 1991:644-666. - PubMed
CAST 1989
    1. Cardiac arrhythmia suppression trial (CAST) investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. New England Journal of Medicine 1989;321:406-412. - PubMed
Cepeda 2003
    1. Cepeda MS, Africano JM, Polo R, Alcala R, Carr DB. What decline in pain intensity is meaningful to patients with acute pain? [What decline in pain intensity is meaningful to patients with acute pain?]. Pain 2003;105:151-7. - PubMed
De Clive‐Lowe 1958
    1. De Clive-Lowe SG, Desmond J, North J. Intravenous lignocaine anesthesia. Anesthesiology 1958;13:138-46. - PubMed
Dunlop 1988
    1. Dunlop R, Davies RJ, Hockley J, Turner P. Analgesic effects of oral flecainide. Lancet 1988;1:420. - PubMed
Dunlop 1991
    1. Dunlop RJ, Hockley JM, Tate T, Turner P. Flecainide in cancer nerve pain. Lancet 1991;337:1347. - PubMed
Dworkin 2003
    1. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett G, Bushnell M, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein S. Advances in Neuropathic Pain: Diagnosis, Mechanisms, and Treatment Recommendations. Arch Neurol 2003;60(11):1524-34. - PubMed
Farrar 2000
    1. Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain 2000;88(3):287-94. - PubMed
Farrar 2001
    1. Farrar JT, Young JP Jr LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94(2):149-58. - PubMed
Feinstein 1997
    1. Feinstein AR, Horwitz RI. Problems in the "evidence" of "evidence-based medicine". American Journal of Medicine 1997;103(6):529-35. - PubMed
Fergusson 2004
    1. Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ 2004;328(7437):432. - PMC - PubMed
Galer 1993
    1. Galer BS, Miller KV, Rowbotham MC. Response to intravenous lidocaine infusion differs based on clinical diagnosis and site of nervous system injury. Neurology 1993;43(6):1233-5. - PubMed
Gilbert 1951
    1. Gilbert CR, Hanson IR, Brown AB, Hingson RA. Intravenous use of xylocaine. Curr Res Anesth Analg 1951;30:301-13. - PubMed
Hedges 2001
    1. Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. Psychological Methods 2001;6(3):203-17. - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carrol D. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12. - PubMed
Kalso 1998
    1. Kalso E, Tramer MR, McQuay HJ, Moore RA. Systemic local-anaesthetic-type drugs in chronic pain: a systematic review. European Journal of Pain 1998;2(1):3-14. - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analysis. Annals of Internal Medicine 2001;135:982-989. - PubMed
Lau 1997
    1. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Annals of Internal Medicine 1997;127:820-826. - PubMed
Lefebvre 2001
    1. Lefebvre C, Clarke MJ. Identifying randomised trials. In: Egger M, Smith GD, Altman DG, editors(s). Systematic reviews in health care. Meta-analysis in context. 2nd edition. London: BMJ Publishing Group, 2001:69-86.
Lindblom 1984
    1. Lindblom U. Reduction of hyperpathia indicates pain relief. Pain 1984;18(3):322. - PubMed
Mao 2000
    1. Mao J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain 2000;87(1):7-17. - PubMed
Merskey 1994
    1. Merskey H, Bogduk N. Classification of chronic pain: description of chronic pain syndromes and definitions of pain terms. In: Merskey H, Bogduk N, editors(s). IASP publication. 2nd Edition. Seattle, WA: IASP Press, 1994:222.
Nagy 1996
    1. Nagy I, Woolf CJ. Lignocaine selectively reduces C fibre-evoked neuronal activity in rat spinal cord in vitro by decreasing N-methyl-D-aspartate and neurokinin receptor-mediated post-synaptic depolarizations; implications for the development of novel centrally acting analgesics. Pain 1996;64(1):59-70. - PubMed
Petersen 1986
    1. Petersen P, Kastrup J, Zeeberg I, Boysen G. Chronic pain treatment with intravenous lidocaine. Neurol Res 1986;8(3):189-90. - PubMed
Rogers 2000
    1. Rogers WH, Wittink HM, Ashburn MA, Cynn D, Carr DB. Using the "TOPS," an Outcomes Instrument for Multidisciplinary Outpatient Pain Treatment. Pain Medicine 2000;1(1):55. - PubMed
Sindrup 1999
    1. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 1999;83:389-400. - PubMed
Sindrup 2000
    1. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000;55(7):915-20. [MEDLINE: ] - PubMed
Soares 2004
    1. Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B. Bad reporting does not mean bad methods for randomized trials: Observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ 2004;328:22-5. - PMC - PubMed
Sriwatanakul 1982
    1. Sriwatanakul K, Kelvie W, Lasagna L. The quantification of pain: an analysis of words used to describe pain and analgesia in clinical trials. Clinical Pharmacology and Therapeutics 1982;32(2):143-8. - PubMed
Turk 2003
    1. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003;106(3):337-45. - PubMed
Woolf 1985
    1. Woolf CJ, Wiesenfeld-Hallin Z. The systemic administration of local anesthetics produces a selective depression of C-afferent fiber evoked activity in the spinal cord. Pain 1985;23:361-374. - PubMed

MeSH terms